ALNOX.PA

NOXXON Pharma N.V., a biopharmaceutical enterprise founded in 1997 and based in Berlin, Germany, is currently in the clinical phase of developing its unique cancer treatments. The company utilizes its proprietary Spiegelmer platform to cultivate a portfolio of clinical-stage drug candidates. Its primary oncology asset, NOX-A12, is being investigated as a combination therapy for various challenging cancer types, including metastatic pancreatic and colorectal cancer, glioblastoma, myeloma, and chronic lymphocytic leukemia. Beyond its cancer focus, NOXXON has also advanced NOX-E36, which has successfully concluded Phase 1/2 clinical trials for its potential application in diabetic nephropathy. Furthermore, NOXXON has entered into a collaborative agreement with Merck & Co. Inc. This partnership aims to assess NOX-A12's performance when administered alongside Keytruda (pembrolizumab), an inhibitor antibody, in individuals suffering from metastatic solid tumors.